Dr. Elin Haf Davies Withdraws From CTD Holdings' Family and Physicians Listening Circle on NPC Treatment
Marketwired - Fri Jul 10, 8:16AM CDT
CTD Holdings, Inc. (OTCQB: CTDH), a family of biotechnology growth companies that distribute and manufacture cyclodextrin-based products, today announced that Dr. Elin Haf Davies of London, UK, has notified the company that she will be unable to serve as a member of the company's Family and Physicians Listening Circle due to an unforeseen business conflict. CTD had recently announced that Dr. Davies had agreed to join its Listening Circle, which serves as an information sharing forum for families, physicians, and CTD's International Clinical Program team working to develop the orphan drug designated Trappsol® Cyclo(TM) for the treatment of Niemann-Pick Type C (NPC), a rare and fatal disease found primarily in children.
CTD Holdings Ships Additional Trappsol(R) Cyclo(TM) to Brazil
Marketwired - Tue Jun 30, 6:00AM CDT
CTD Holdings, Inc. (OTCQB: CTDH), a family of biotechnology growth companies that develop cyclodextrin-based treatments, today announced that the company is shipping 608 additional vials of its Trappsol(®) Cyclo((TM)) product to the government of Brazil under a business relationship now in its fifth year.
CTD Holdings receives sponsorship of the US FDA Orphan Drug Designation for Trappsol Cyclo from UCSF Benioff Children's Hospital Oakland
M2 - Thu Jun 25, 5:08AM CDT
Biotechnology company CTD Holdings (OtherOTC:CTDH) revealed on Wednesday the launch of an agreement to acquire the sponsorship of the US FDA Orphan Drug Designation for Trappsol Cyclo from UCSF Benioff Children's Hospital Oakland.
CTD Holdings Obtains US Orphan Drug Designation for Trappsol(R) Cyclo(TM)
Marketwired - Wed Jun 24, 6:00AM CDT
CTD Holdings, Inc. (OTCQB: CTDH), a family of biotechnology growth companies that develop cyclodextrin-based treatments, today announced that the company has signed an agreement with UCSF Benioff Children's Hospital Oakland to transfer sponsorship of their US FDA Orphan Drug Designation for Trappsol® Cyclo(TM) to CTD Holdings. CTD's orphan drug designated Trappsol® Cyclo(TM) is being developed for the treatment of Niemann-Pick Type C (NPC), a rare and fatal disease found primarily in children.
Dr. Begona Arias Joins CTD Holdings' Family and Physicians Listening Circle on NPC Treatment
Marketwired - Wed Jun 10, 6:00AM CDT
CTD Holdings, Inc. (OTCQB: CTDH), a family of biotechnology growth companies that distribute and manufacture cyclodextrin-based products, today announced that Dr. Begoña Arias of Hospital Sanitas la Zarzuela, Madrid, will become a member of the company's Family and Physicians Listening Circle. This group serves as an information sharing forum for families, physicians, and CTD's International Clinical Program team working to develop orphan drug designated Trappsol® Cyclo(TM) for the treatment of Niemann-Pick Type C (NPC), a rare and fatal disease found primarily in children.
CTD Holdings Announces Family and Physicians Listening Circle on NPC Treatment
Marketwired - Mon Jun 08, 6:01AM CDT
CTD Holdings, Inc. (OTCQB: CTDH), a family of biotechnology growth companies that distribute and manufacture cyclodextrin-based products, today announced the Family and Physicians Listening Circle, which will serve as an information sharing forum for families, physicians, and CTD's International Clinical Program team working to develop orphan drug designated Trappsol® Cyclo(TM) for the treatment of Niemann-Pick Type C (NPC), a rare and fatal disease found primarily in children.
CTD Holdings Names Dr. Benny Liu, M.D. to Scientific Advisory Board
Marketwired - Mon May 18, 6:01AM CDT
CTD Holdings, Inc. (OTCQB: CTDH), a family of biotechnology growth companies that distribute and manufacture cyclodextrin-based products, including the orphan drug designated Trappsol® Cyclo(TM), today announced the appointment of Dr. Benny Liu, M.D. to the company's Scientific Advisory Board.
CTD Holdings to appoint Dr James E.K. Hildreth to its scientific advisory board
M2 - Tue May 05, 4:34AM CDT
Biotechnology company CTD Holdings (OtherOTC:CTDH) disclosed on Monday the election of Professor James E.K. Hildreth, MD, PhD to its scientific advisory board effective 1 July 2015.
CTD Holdings Names Professor James E.K. Hildreth to Scientific Advisory Board
Marketwire Canada - Mon May 04, 6:17AM CDT
CTD Holdings, Inc. (OTCQB: CTDH), a family of biotechnology growth companies that distribute and manufacture cyclodextrin-based products, today announced the appointment of Professor James E.K. Hildreth, M.D., Ph.D. to the company's Scientific Advisory Board effective July 1, 2015. Dr. Hildreth was recently named President and Chief Executive Officer of Meharry Medical College, the nation's largest private, independent historically black academic health sciences center.
CTD Holdings Expands International Clinical Program Team
Marketwired - Tue Apr 28, 6:01AM CDT
CTD Holdings, Inc. (OTCQB: CTDH), a family of biotechnology growth companies that develop cyclodextrin-based treatments and other products, today announced the expansion of its International Clinical Program Team to include Aptus Clinical, Boyd Consultants and KJC Statistics. The clinical research specialists join Accenture in the development of orphan drug Trappsol® Cyclo(TM) for Europe and other markets. Together, Accenture, Aptus, Boyd and KJC bring strong international experience to CTD's orphan drug development program.
Baltimore Sun Publishes Op-Ed by CTD Executive Chairman and Scientific Advisory Board Member
Marketwired - Tue Apr 21, 6:01AM CDT
CTD Holdings, Inc. (OTCQB: CTDH) Executive Chairman of the Board N. Scott Fine and Scientific Advisory Board Member Dr. Sharon H. Hrynkow have co-authored a highly insightful and thoughtful op-ed in The Baltimore Sun titled, "Building Local Capacity to Fight Epidemics," which states that the most effective way to stop viruses such as Ebola, MERS and Chikungunya from becoming global pandemics is to prevent them from spreading beyond their point of origin. To do so, local medical virologists in every country must receive training and support that allow them to develop and implement programs that contain and combat viruses.